
The best knee braces, according to physical therapists and orthopedists
Compression knee brace: Copper Fit Freedom Knee Compression Sleeve
Patella support knee brace: Bauerfiend GenuTrain Knee Support Brace
Wraparound knee brace: BioSkin Wraparound Patella Stabilizer
Hinged knee brace: DonJoy Performance Hinged Knit Knee Brace If you're recovering from an injury or just looking for a bit of stability during activity, the best knee brace for your needs should keep you feeling comfortable, supported and safe. But finding the right brace can be tricky depending on the type of support your joint needs.
Not to worry. We spoke to orthopedic surgeons and physical therapists about a range of knee brace designs and options so you can be on the mend quickly. While this list can certainly serve as a starting point for your quest for better joint support, you'll definitely want to consult your primary health care provider before making a decision on the right knee brace for you. Bonus: They'll also be able to offer some exercises to help with knee pain to maximize your recovery and ultimate comfort.
Copper Fit Freedom Knee Compression Sleeve
'This is a good brace for general support for daily activity or with aerobic activity,' Dr. Sudheer Reddy, a board-certified orthopedic surgeon at Shady Grove Orthopaedics, said. He recommends the sleeve since it's comfortable to wear and slim enough to fit under clothing. Since it features grippy bands around the top and bottom to make sure it stays in place while you move, it's an especially great option for active folks who tend to sweat. It's also a budget-friendly find, coming in under $15.
DonJoy Drytex Sport Hinged Knee Sleeve
Reddy likes this knee brace because of the stability its hinges provide and because it's made with DonJoy's Drytex fabric. He called the fabric 'an alternative to neoprene' (which some wearers may find causes hot spots) and noted that it allows for greater breathability, which is ideal for higher sweat activities like running. Its hinges on both sides create crucial stability, but you'll still experience flexibility without feeling restricted.
DonJoy Performance Hinged Knit Knee Brace
Alexandra D'Annibale, a physical therapist at Spear Center, recommends this brace because it's designed with a four-way stretch material that will accommodate your joints as you move throughout the day. It features removable plastic hinges, which promote both medial and lateral stability, but if you don't need them, you can always remove them for more of a sleeve-like fit. Its patella buttress is designed to support your kneecap, and the compressive design helps minimize swelling.
Breg Recover Knee Brace
'This is a hinged knee brace that features 'drop locks' that can help restrict motion and guide rehabilitation for individuals recovering from injury or surgery,' Reddy said. "It is very good at restricting side-to-side motion at the knee that can increase chances of injury.' This brace is bulkier than other options on the market, meaning it might not create a streamlined fit under tighter clothes. But it can be locked in five different positions and has a universal fit to suit both your right and left legs.
CVS Knee Support Sleeve
D'Annibale explained that compression sleeves are knee braces that offer mild support and can help reduce swelling without restricting your range of motion. She recommends this simple CVS brand support sleeve that's easy to wash after wear, offers flexible support and comes in four different sizes so you can find one that fits just right. Your kneecap should sit just under the lighter part of the fabric, which helps you guide the brace into the right spot.
Breg Hinged Knee Support Brace
'This is a good wraparound brace with cushioning around the patella and a breathable material,' Reddy said of this brace for mild ligament instabilities. He appreciates its adjustable straps that prevent it from sliding down and that the brace is overall easy to put on and fit around your joint. It's also washable thanks to its removable hinges.
Bauerfiend GenuTrain Knee Support Brace
'Most often, I recommend the open-kneecap sleeve to support patella tracking or one of the Bauerfeind Knee Supports, which come with a gel pad that sits around the patella,' Darcie Pervier, a physical therapist and owner of Newburyport Wellness in Massachusetts, told CNN Underscored contributor Marissa Miller for this story. 'The Bauerfeind supports are made with a knit fabric that is breathable, and when fitted well, they don't slide down as easily as many sleeves."
DonJoy Tru-Pull Lite Knee Brace
'Pain in the front of the knee, called patellofemoral pain, is a common problem encountered by patients,' Reddy said. 'Issues can range from arthritis of the patellofemoral joint to patellar instability ([when the] kneecap can slide out of place).' Reddy recommends this wraparound brace because of the lateral buttress strap that helps stabilize the patella during activity. The strap doesn't just secure the brace around your thigh and calf; it pulls the whole device to fit around the whole of your knee joint.
Breg Fusion OA Plus Knee Brace
If you're looking for something top-of-the-line, Reddy suggests this brace from Breg. 'Knee arthritis is very common in individuals. While this brace is bulkier and more expensive, it's helpful in reducing stress to the arthritic parts of the knee during activity,' he said. Reddy also likes that it has adjustable Velcro straps that help tailor fit to a person's knee and it features hinges on either side to help support the knee and allow freedom of movement during activity. Use it for low-impact activities such as walking, tennis and golf.
DonJoy Performance Bionic Knee Brace
Pervier told us this brace is light enough to wear while you're fairly active, but it still offers more physical support than a sleeve due to its hinges, which provide lateral support. The brace also has anti-slip technology to keep it in place while you're moving, and adjustable straps for a customized fit. Pervier notes that even though it offers decent lateral stability, this brace isn't designed for major knee injuries.
BioSkin Wraparound Patella Stabilizer Knee Brace
Julie Landis, a physical therapist and certified professional ergonomist, told Miller she recommends this neoprene option from BioSkin. The fabric makes the brace easy to slide on, and Landis notes the compression can help reduce pain and swelling. In addition to adjustable straps at the top and bottom of the brace, this option has a patellar tracking strap that can be positioned medially or laterally. Landis said this feature can 'help properly guide and control its movement during bending and straightening.'
Mueller Sports Medicine Self-Adjusting Hinged Knee Brace
If you're looking for a more budget-friendly option, this pick from Mueller Sports Medicine is under $30. Lisa Chase, an orthopedic and sports physical therapist and owner of Back 2 Normal Physical Therapy, spoke with Miller and recommends this affordable option because it offers moderate stabilization but is still comfortable and versatile. It's made from a neoprene material that's comfortable for long wear, allowing for flexibility while you move. It's another hinged option to provide lateral stability.
Shock Doctor Ultra Knit Knee Support
Chase told CNN Underscored that she likes this brace for athletes who need both compression and stability. This compressive brace comes in four sizes and has been designed with a moisture-wicking material. This will help wick away sweat during a grueling workout. Its patella gel buttress helps provide support and cushioning to your patella (without a cumbersome wraparound strap) so it's easy to put on and remove.
Neenca Hinged Knee Brace
Landis told us that she recommends this hinged brace from Neenca. If you're healing from an injury, this brace is designed to block movement, restricting your joint to a safe range of motion or maintaining it in a fixed position. The sides of this brace have two-sided locking dials, which fix the brace in place and can be unlocked to adjust your range of motion.
Dr. Brace Professional Knee Brace
Four adjustable straps, patella gel pads and side stabilizers round out this brace. Pervier recommends a wraparound brace for clients who may be struggling with arthritis in their hands as well as their knees, since the brace is easier than others to slide on compared to a sleeve. This pick from Dr. Brace offers both light compression and stability for the joint. If your doctor has recommended a knee brace, chances are they have walked you through what to look for to best address your unique situation. But if you're dealing with an old injury or just looking for extra support, there are lots of options on the market that can help fast-track your healing.
Type of knee brace
There are two types of knee braces to consider. The first is a compression sleeve, which is designed to help with swelling and offer mild support. D'Annibale noted these types of braces typically don't restrict your joint movement. The other kind is a hinged brace, which D'Annibale said is used for joint stability and protection. Hinged braces don't provide compression.
Material
You'll also want to consider the material of the brace. If you're looking to wear a brace while playing sports, walking, running or participating in higher-impact activities that promote sweat production, look for something washable and sweat-wicking. While neoprene is a fabric our experts called out for its comfort and breathability, Lynn J. Berman, owner and physical therapist at Spring Forward PT, noted you'll also find knee sleeves made with copper-infused material and fabric sleeves. These materials can offer sweat-wicking properties or have a more thin, streamlined design for wearing under clothes.
Activity
For a knee brace best suited for your purposes, D'Annibale suggests identifying what type of activity you'll be wearing it for. She noted that the style of brace will vary whether you're using it for everyday activity or for post-operation support. If you're unsure, consult a physical therapist to determine what type of support you might need before you make your purchase.
The following FAQs were answered by Lynn J. Berman, owner and physical therapist at Spring Forward PT and Alexandra D'Annibale, a physical therapist at Spear Center.
Are knee braces considered compression?
Are knee braces considered compression?
The simple answer is no. Not all knee braces are considered compression braces. Specific knee braces offer compression, so you'll have to look for one that does if that's the type of support you require. D'Annibale breaks knee braces down into two categories: compression braces (also referred to as sleeves) and hinged braces. If you're looking for something compressive, you'll typically find that terminology listed in the brace's description.
Can you use a knee brace and a knee sleeve together?
Can you use a knee brace and a knee sleeve together?
'Yes, wearing a compression sleeve [also known as a knee sleeve] under a knee brace is common, particularly following surgery,' D'Annibale said. She noted that the sleeve can help manage swelling while a brace offers structural support during recovery. Structural support can help limit movement of the joint so you don't overexert it while healing.
How do you put on a knee brace?
How do you put on a knee brace?
D'Annibale said that you can put on a compression sleeve by sliding it over your foot and up your leg. She noted you'll want to position the brace so your kneecap is centered and the brace lies flat on your body without bunching anywhere. For hinged braces, she recommended beginning with straps open. Then, position the brace behind your knee, aligning the hinges with the joint. Fasten the straps in the recommended order — typically from bottom to top — ensuring a snug but comfortable fit.
For this article, we consulted the following experts to gain their professional insights.
Lynn J. Berman, owner and physical therapist at Spring Forward PT
Lisa Chase, an orthopedic and sports physical therapist and owner of Back 2 Normal Physical Therapy
Alexandra D'Annibale, a physical therapist with Spear Center
Julie Landis, a physical therapist and certified professional ergonomist
Darcie Pervier, a physical therapist and owner of Newburyport Wellness
Dr. Sudheer Reddy, board-certified orthopedic surgeon at Shady Grove Orthopaedics
CNN Underscored has a team of skilled writers and editors who have many years of experience testing, researching and recommending products, and they ensure each article is carefully edited and products are properly vetted. We talk to top experts when applicable to make certain we are testing each product accurately, recommending only the best products and considering the pros and cons of each item. For this article, writer Ellen McAlpine and contributing editor Marissa Miller spoke with orthopedic doctors and physical therapists to learn more about expert-recommended knee braces. McAlpine compiled this list of braces to help you recover, heal and stay active.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
NHC Reports Second Quarter 2025 Earnings
MURFREESBORO, Tenn., August 08, 2025--(BUSINESS WIRE)--National HealthCare Corporation (NYSE American: NHC), the nation's oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended June 30, 2025 totaled $374,910,000 compared to $300,658,000 for the quarter ended June 30, 2024, an increase of 24.7%. The increase in net operating revenues for the second quarter of 2025 compared to the second quarter of 2024 was due to an 9.6% increase in same-facility net operating revenues, as well as the August 1, 2024 acquisition of White Oak Management, Inc. ("White Oak"). For the quarter ended June 30, 2025, the reported GAAP net income attributable to NHC was $23,722,000 compared to $26,844,000 for the same period in 2024. Excluding the unrealized gains and losses in our marketable equity securities portfolio and other non-GAAP adjustments, adjusted net income for the quarter ended June 30, 2025 was $25,710,000 compared to $15,612,000 for the same period in 2024, an increase of 64.7% (*). The GAAP diluted earnings per share were $1.52 and $1.73 for the quarters ending June 30, 2025 and 2024, respectively. Adjusted diluted earnings per share were $1.65 and $1.00 for the quarters ending June 30, 2025 and 2024, respectively (*). (*) - See the tables below that provide a reconciliation of GAAP to non-GAAP items. About NHCAs of August 1, 2025, NHC affiliates operate for themselves and third parties 80 skilled nursing facilities with 10,329 beds. NHC affiliates also operate 26 assisted living communities with 1,413 units, nine independent living communities with 777 units, three behavioral health hospitals, 34 homecare agencies, and 33 hospice agencies. NHC's other services include Alzheimer's and memory care units, pharmacy services, a rehabilitation services company, and providing management and accounting services to third party post-acute operators. Other information about the company can be found on our web site at Non-GAAP Financial PresentationThe Company is providing certain non-GAAP financial measures as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. Therefore, the Company believes this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The presentation of this additional non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Forward-Looking StatementsStatements in this press release that are not historical facts are forward-looking statements. NHC cautions investors that any forward-looking statements made involve risks and uncertainties and are not guarantees of future performance. The risks and uncertainties are detailed from time to time in reports filed by NHC with the S.E.C., including Forms 8-K, 10-Q, and 10-K. All forward-looking statements represent NHC's best judgment as of the date of this release. Consolidated Statements of Operations (in thousands, except share and per share amounts) Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Revenues: Net patient revenues $ 363,349 $ 279,918 $ 724,956 $ 565,741 Other revenues 11,561 11,295 23,651 22,648 Government stimulus income - 9,445 - 9,445 Net operating revenues and grant income 374,910 300,658 748,607 597,834 Costs and expenses: Salaries, wages and benefits 226,534 180,076 454,664 363,214 Other operating 91,943 78,154 184,400 155,583 Facility rent 11,328 10,570 22,693 20,918 Depreciation and amortization 11,015 9,338 21,993 19,924 Total costs and expenses 340,820 278,138 683,750 559,639 Income from operations 34,090 22,520 64,857 38,195 Non-operating income 5,132 4,956 9,211 10,641 Interest expense (1,993 ) - (4,099 ) (46 ) Unrealized gains/(losses) on marketable equity securities (5,061 ) 9,124 5,921 23,523 Income before income taxes 32,168 36,600 75,890 72,313 Income tax provision (8,055 ) (9,494 ) (19,487 ) (18,956 ) Net income 24,113 27,106 56,403 53,357 Net income attributable to noncontrolling interest (391 ) (262 ) (476 ) (300 ) Net income attributable to National HealthCare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Net income per common share Basic $ 1.53 $ 1.74 $ 3.62 $ 3.45 Diluted $ 1.52 $ 1.73 $ 3.59 $ 3.42 Weighted average common shares outstanding Basic 15,462,135 15,391,535 15,450,286 15,371,150 Diluted 15,599,638 15,555,612 15,587,783 15,530,624 Dividends declared per common share $ 0.64 $ 0.61 $ 1.25 $ 1.20 Balance Sheet Data June 30 December 31 (in thousands) 2025 2024 (unaudited) Cash, cash equivalents and marketable securities $ 257,628 $ 216,185 Restricted cash, cash equivalents and marketable securities 169,340 163,795 Current assets 463,227 424,408 Property and equipment, net 676,619 684,289 Total assets 1,562,220 1,524,429 Current liabilities, excluding current long-term debt 261,245 227,297 Current and long-term debt 110,000 137,000 NHC stockholders' equity 1,021,905 980,161 Selected Operating Statistics Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Skilled Nursing Per Diems: Medicare $ 614.85 $ 577.71 $ 613.47 $ 579.81 Managed Care 486.17 447.96 489.30 459.48 Medicaid 286.43 264.49 284.07 264.88 Private Pay and Other 341.34 312.91 339.24 310.31 Average Skilled Nursing Per Diem $ 361.42 $ 338.86 $ 360.78 (1) $ 341.21 (1) Skilled Nursing Patient Days: Medicare 83,615 74,602 169,869 155,758 Managed Care 83,015 62,957 166,661 128,388 Medicaid 368,687 279,504 732,329 561,325 Private Pay and Other 194,202 150,234 378,796 307,677 Total Skilled Nursing Patient Days 729,519 567,297 1,447,655 (1) 1,153,148 (1) (1) NHC exited three skilled nursing facilities in Missouri on March 1, 2024. For the six months ended June 30, 2024, the exited Missouri skilled nursing facilities had an average skilled nursing per diem of $275.64 and 20,267 patient days. The tables below provide reconciliations of GAAP to non-GAAP items (in thousands, except per share amounts): Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Net income attributable to National Healthcare Corporation $ 23,722 $ 26,844 $ 55,927 $ 53,057 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 5,061 (9,124 ) (5,921 ) (23,523 ) Operating losses for newly-opened operations not at full capacity - 20 - 20 Gain on sale of property and equipment (3,606 ) - (3,606 ) - Gain on sale of unconsolidated company - - - (1,024 ) Stock-based compensation expense 1,232 1,176 2,260 1,969 Acquisition-related expenses - 2,194 - 2,194 Employee retention credit - (9,445 ) - (9,445 ) Income tax provision/(benefit) on non-GAAP adjustments (699 ) 3,947 1,889 7,750 Non-GAAP Net income $ 25,710 $ 15,612 $ 50,549 $ 30,998 GAAP diluted earnings per share $ 1.52 $ 1.73 $ 3.59 $ 3.42 Non-GAAP adjustments Unrealized (gains)/losses on marketable equity securities 0.32 (0.59 ) (0.38 ) (1.51 ) Gain on sale of property and equipment (0.23 ) - (0.23 ) - Gain on sale of unconsolidated company - - - (0.07 ) Stock-based compensation expense 0.08 0.08 0.14 0.13 Acquisition-related expenses - 0.14 - 0.14 Employee retention credit - (0.61 ) - (0.61 ) Income tax provision/(benefit) on non-GAAP adjustments (0.04 ) 0.25 0.12 0.50 Non-GAAP diluted earnings per share $ 1.65 $ 1.00 $ 3.24 $ 2.00 View source version on Contacts Brian F. Kidd, SVP/CFOPhone: (615) 890-2020
Yahoo
8 minutes ago
- Yahoo
Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins
Tempus AI Inc. (NASDAQ:TEM) reported second-quarter financial results Friday. The AI-focused precision medicine and patient care company reported a second-quarter adjusted loss of 22 cents per share, beating analyst estimates for a loss of 24 cents per share. Tempus AI reported quarterly revenue of $314.64 million, beating the consensus estimates of $296.85 million. Revenue increased 89.6% year-over-year. Genomics contributed $241.8 million in revenue in the quarter, growing 115.3% year over testing (Tempus genomics) delivered $133.2 million of revenue, up 32.9%, with approximately 26% volume growth versus 20% last quarter. Hereditary testing sales (Ambry genetics) reached $97.3 million, up 33.6% year-over-year on a pro forma basis with approximately 32% volume growth. Revenue from Data and services totaled $72.8 million, delivering 35.7% growth versus the second quarter of 2024, led by Insights (data licensing), which grew 40.7% year-over-year. Adjusted EBITDA of ($5.6 million) in the second quarter of 2025 compared to ($31.2 million) in the second quarter of 2024, an improvement of $25.6 million year-over-year. View more earnings on TEM 'The business is performing well with revenues and margins growing faster than expected, contributing to our continued improvement in adjusted EBITDA on a year-over-year basis,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We saw significant re-acceleration of our clinical volumes, which grew 30% in the quarter, as we delivered more than 212,000 NGS tests,' Lefkofsky said in a statement on Friday. Database Update Through more than 4,500 integrations, Tempus said it connected to more than 40 million clinical patient records, with around 9 million de-identified and ingested, spanning approximately 1.1 billion healthcare documents, a significant percentage of which are connected to the around 4 million samples the company has sequenced. As a result, the company's database stands at over 350 petabytes of connected clinical and molecular data. Tempus AI ended the quarter with $293.0 million in cash and marketable securities, an improvement of around $70 million over last quarter. Outlook Tempus AI increased its guidance and expects a full year of 2025 revenue of approximately $1.26 billion for the consolidated business, representing approximately 82% annual growth, compared to the consensus of $1.25 billion. Earlier, the company expected revenue between $1.24 billion and $1.25 billion for its consolidated Tempus and Ambry Genetics business. The company reaffirms full-year 2025 adjusted EBITDA of $5 million, an improvement of approximately $110 million over 2024. Tempus AI received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software in July. Tempus said the FDA granted it 510(k) clearance for its Tempus ECG-Low EF software, which uses AI to identify patients with a potential left ventricular ejection fraction. Price Action: Tempus AI shares were up 5.79% after hours, trading at $55.21 at the time of publication on Tuesday. Read Next:Photo by Piotr Swat via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
8 minutes ago
- Yahoo
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open and actively recruiting patients Strengthened clinical leadership and bolstered roster of scientific advisors with additions to Board of Directors and creation of Research and Innovation Advisory Board Strategic cost realignment of approximately 30%, primarily through a workforce reduction Cash and cash equivalents of $721.5 million as of June 30, 2025, with expected financial runway extended into 2028 CAMBRIDGE, England & BOSTON, August 08, 2025--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. "We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation precision-guided therapeutics that have the potential to help patients live longer and live well," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "We are energized by the progress we are making across our pipeline, and with this momentum, we are pleased to welcome our new Research and Innovation Advisory Board members, as well as new Board member Charles Swanton, to further our innovation and strategic growth." Dr. Lee continued: "As we advance our various pipeline programs that hold strong potential for changing the treatment paradigm for patients with cancer and creating value for shareholders, Bicycle remains committed to disciplined capital allocation. Today we announced organizational streamlining efforts that provide us with operational flexibility to deliver potentially value-generating datasets while strengthening our financial position in uncertain market conditions. Saying goodbye to talented team members is very difficult, and we sincerely thank them for their dedication to our company. We believe Bicycle is strongly positioned to realize our strategic priorities and milestones and look forward to providing key program updates over the second half of this year." Second Quarter 2025 and Recent Events Presented additional human imaging data for an early Bicycle Radioconjugate® (BRC®) molecule targeting MT1-MMP at the American Association for Cancer Research (AACR) Annual Meeting 2025. A poster presentation included new data from a second patient who underwent MT1-MMP-PET/CT imaging that build on previously announced data. Altogether, the data continue to validate the potential of MT1-MMP as a novel cancer target and demonstrate the positive properties of BRC molecules for radiopharmaceutical imaging. Imaging data from these two patients are representative of the data generated to date in 12 out of 14 patients with various solid Therapeutics continues to advance its emerging BRC pipeline, with initial EphA2 human imaging data expected in 2H 2025 and company-sponsored clinical trials planned for 2026. Presented two abstracts highlighting the development of Bicycle® Drug Conjugate (BDC®) zelenectide pevedotin for metastatic urothelial cancer (mUC) at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting. The abstracts outlined previously disclosed topline combination data for zelenectide pevedotin plus pembrolizumab in first-line mUC from the Phase 1/2 Duravelo-1 trial and provided an overview of the ongoing Phase 2/3 Duravelo-2 registrational trial for zelenectide pevedotin in Therapeutics is on track to provide an update on dose selection from the Duravelo-2 trial and the accelerated approval pathway for zelenectide pevedotin in mUC following a meeting with the U.S. Food and Drug Administration planned for 4Q 2025. Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer (NSCLC) open and actively recruiting patients. Duravelo-4 is Bicycle Therapeutics' second trial to leverage NECTIN4 gene amplification as a biomarker for patient selection and to expand the development of zelenectide pevedotin for additional solid several trials underway assessing the potential for zelenectide pevedotin to treat mUC, breast cancer and lung cancer, the company has decided to pause the previously announced Phase 1/2 Duravelo-5 trial in multiple tumors. Expanded Board of Directors with the addition of Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, current chair of Bicycle Therapeutics' Clinical Advisory Board. Dr. Swanton leads the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute. His research focuses on how tumors evolve over space and time, developing an understanding of branching evolutionary histories of solid tumors, processes that drive cancer cell-to-cell variation and the impact of cancer diversity on effective immune surveillance and clinical outcomes. Dr. Swanton is a fellow of the Royal Society, a fellow of the Royal College of Physicians and a fellow of the Academy of Medical Sciences. He completed his M.D. and Ph.D. training at the Imperial Cancer Research Fund Laboratories. Formed Research and Innovation Advisory Board (RAB) to support scientific advancement and strategic growth across preclinical programs. The RAB replaces Bicycle's Scientific Advisory Board. Inaugural RAB members include: Jose-Carlos Gutierrez-Ramos, Ph.D., is a director on the Bicycle Therapeutics Board of Directors. He also serves as the chief science officer at Danaher Corporation, leading the Danaher Innovation Centers and the Danaher Scientific Advisory Board. Previously, Dr. Gutierrez-Ramos was head of global drug discovery at AbbVie Inc., group senior vice president of biotherapeutics research and development (R&D) at Pfizer Inc., and senior vice president and CEDD head of immuno-inflammation at GlaxoSmithKline plc. He was also the founding CEO and president of Repertoire Immune Medicine, where he built and led a team focused on decoding the human immunome. Prior to that, he served as president and CEO of Synlogic, Inc. Dr. Gutierrez-Ramos earned a Ph.D. from the immunology department of the Center for Molecular Biology at the Universidad Autonoma de Madrid, and a B.S., summa cum laude, in chemistry with a minor in biochemistry from the Universidad Complutense de Madrid. Jason Lewis, Ph.D., is the Emily Tow Chair at Memorial Sloan Kettering Cancer Center (MSKCC) and currently serves as the deputy director at the Sloan Kettering Institute, overseeing the Office of Scientific Education and Training. He is also the scientific director of the Radiochemistry and Molecular Imaging Probe Core Facility at MSKCC. Dr. Lewis is a laboratory head in Sloan-Kettering Institute's molecular pharmacology program and serves as a professor at the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Medical College. He earned a Ph.D. in biochemistry from the University of Kent and an M.S. and B.S. in chemistry from the University of Essex. Robert Lutz, Ph.D., is a consultant/advisor to biotech and pharma with more than 30 years of experience with a significant focus on the development of antibody-drug conjugates (ADCs). He currently serves as chief scientific officer of Iksuda Therapeutics and is a board member and chief development officer of Synthis Therapeutics. Prior to his consulting practice, Dr. Lutz was vice president of translational research and development at ImmunoGen, where he was responsible for the advancement of multiple ADC programs, including KADCYLA® (ado-trastuzumab emtansine), the first ADC to be approved for solid tumor indications, and ELAHERE® (mirvetuximab soravtansine). He earned a Ph.D. in biochemistry from Brandeis University and a B.S. in biochemistry from the University of New Hampshire. Michael Hofman, MBBS, FRACP, FAANMS, FICIS, GAICD, is a nuclear medicine physician and professor at the Sir Peter MacCallum Department of Oncology at the University of Melbourne in Australia. His research has been instrumental in advancing PSMA PET imaging and PSMA radioligand therapy, helping to revolutionize the diagnosis and treatment of prostate cancer. He was named Australia's top researcher in nuclear medicine, radiotherapy and molecular imaging in both 2024 and 2025. Professor Hofman leads the PET/CT program and the Prostate Cancer Theranostics and Imaging Centre of Excellence at Peter MacCallum Cancer Centre. He earned a degree in medicine and surgery from Monash University in Australia and undertook a PET/CT fellowship at St. Thomas' Hospital in London. Welcomed Michael Method, M.D., as senior vice president of clinical development. Dr. Method is an academic and clinical gynecologic oncologist with extensive drug development experience. He most recently served as a senior vice president of clinical development at Karyopharm Therapeutics, Inc., after his time as an executive medical director at ImmunoGen, Inc. where he led global clinical development for gynecologic and female malignancies. Previously, Dr. Method was a senior medical advisor for global medical affairs at Eli Lilly, focused on breast cancer. He earned his M.D. and MPH from Northwestern University, and his B.S. in biochemistry and MBA from the University of Notre Dame. Participation in Upcoming Investor Conferences Bicycle Therapeutics management will participate in the following investor conferences in September: Cantor Global Healthcare Conference on Thursday, Sept. 4; fireside chat at 3:55 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sept. 9; fireside chat at 7:45 a.m. ET Live webcasts of the fireside chats will be accessible in the Investor section of the company's website at Archived replays of the webcasts will be available following the fireside chat dates. Second Quarter 2025 Financial Results Cash and cash equivalents were $721.5 million as of June 30, 2025, compared to $879.5 million as of December 31, 2024. The decrease in cash and cash equivalents is primarily due to cash used in operations, including increased cash payments for clinical program activities. R&D expenses were $71.0 million for the three months ended June 30, 2025, compared to $40.1 million for the three months ended June 30, 2024. The increase in expense of $30.9 million was primarily due to increased clinical program expenses for zelenectide pevedotin development, increased discovery, platform and other expenses, and increased personnel-related costs, offset by decreased clinical program expenses for Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) molecules as well as higher U.K. R&D tax credits period over period. General and administrative expenses were $18.5 million for the three months ended June 30, 2025, compared to $15.9 million for the three months ended June 30, 2024. The increase in expense of $2.6 million was primarily due to increased personnel-related costs, as well as increased professional and consulting fees. Net loss was $79.0 million, or $(1.14) basic and diluted net loss per share, for the three months ended June 30, 2025, compared to net loss of $39.8 million, or $(0.77) basic and diluted net loss per share, for three months ended June 30, 2024. In recognition of the evolving macroeconomic environment and the importance of preserving capital, Bicycle Therapeutics is implementing a workforce reduction and taking other steps to optimize its operations and extend the company's expected financial runway. These strategic cost realignment efforts are being implemented to prioritize potentially high-impact, value-generating programs, which include the advancement of zelenectide pevedotin, BT5528, next-generation Bicycle® Drug Conjugates and the company's wholly owned pipeline of Bicycle® Radioconjugates. Bicycle Therapeutics anticipates total operational savings of approximately 30% over the course of the financial runway period. These actions are expected to extend the financial runway into 2028 and strengthen the company's ability to weather continued market uncertainty as it advances clinical programs through key milestones. About Bicycle TherapeuticsBicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Drug Conjugate (BDC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BDC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit Forward Looking StatementsThis press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the validation of MT1-MMP as a cancer target and BRC molecules having positive properties for radiopharmaceutical imaging; the initiation of new clinical trials, the progress of Bicycle's ongoing clinical trials and the timing of EphA2 human imaging data and updates on dose selection in the Duravelo-2 clinical trial and accelerated approval pathway; the outcome of Bicycle's strategic cost realignment efforts and Bicycle's expected financial runway; and the use of Bicycle Therapeutics' technology through various partnerships to develop therapies for diseases beyond oncology. Bicycle Therapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in research and development and in the initiation, progress and completion of clinical trials and clinical development of Bicycle Therapeutics' product candidates; the risk that Bicycle Therapeutics may not realize the intended benefits of its cost realignment efforts; the risk that Bicycle's projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated; and other important factors, any of which could cause Bicycle Therapeutics' actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled "Risk Factors" in Bicycle Therapeutics' Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 1, 2025, as well as in other filings Bicycle Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle Therapeutics expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Bicycle Therapeutics plc Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Collaboration revenue $ 2,920 $ 9,361 $ 12,897 $ 28,891 Operating expenses: Research and development 71,029 40,059 130,087 74,923 General and administrative 18,493 15,949 39,616 32,331 Total operating expenses 89,522 56,008 169,703 107,254 Loss from operations (86,602) (46,647) (156,806) (78,363) Other income (expense): Interest and other income 7,473 7,774 15,887 13,398 Interest expense (54) (824) (105) (1,645) Total other income, net 7,419 6,950 15,782 11,753 Net loss before income tax provision (79,183) (39,697) (141,024) (66,610) (Benefit from) provision for income taxes (231) 115 (1,318) (235) Net loss $ (78,952) $ (39,812) $ (139,706) $ (66,375) Net loss per share, basic and diluted $ (1.14) $ (0.77) $ (2.02) $ (1.40) Weighted average ordinary shares outstanding, basic and diluted 69,252,009 51,992,034 69,224,629 47,276,062 Balance Sheets Data (In thousands) (Unaudited) June 30, December 31, 2025 2024 Cash and cash equivalents $ 721,451 $ 879,520 Working capital 726,840 861,375 Total assets 832,184 956,868 Total shareholders' equity 668,915 793,060 View source version on Contacts Investors: Stephanie YaoSVP, Investor Relations and Corporate 857-523-8544 Matthew DeYoungArgot Partnersir@ 212-600-1902 Media: Jim O'ConnellWeber Shandwickmedia@ 312-988-2343 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data